0.52%| Prev Close: | 4.69 |
|---|---|
| Open: | N/A |
| Bid: | 4.31 x 700 |
| Ask: | N/A |
| 1y Target Est: | 12.00 |
| Beta: | 1.75 |
| Next Earnings Date: | N/A |
| Day's Range: | N/A - N/A |
|---|---|
| 52wk Range: | 2.55 - 6.25 |
| Volume: | 0 |
| Avg Vol (3m): | 234,024 |
| Market Cap: | 173.96M |
| P/E (ttm): | N/A |
| EPS (ttm): | -0.37 |
| Div & Yield: | N/A (N/A) |
Quotes delayed, except where indicated otherwise. Currency in USD.
Headlines
- Regeneron Shareholders Watching Optina Trial Closelyat Seeking Alpha(Wed, May 22)
- Ampio Pharmaceuticals Announces Participation at the UBS Global Healthcare ConferencePR Newswire(Mon, May 13)
- AMPIO PHARMACEUTICALS, INC. FinancialsEDGAR Online Financials(Fri, May 10)
- AMPIO PHARMACEUTICALS, INC. Files SEC form 10-Q, Quarterly ReportEDGAR Online(Fri, May 3)
- Ampio Pharma Initiates Phase III, Investors Extend Momentumat Seeking Alpha(Fri, May 3)
- Major Pharma Companies Refocus R&D Efforts, Aim to Replace Lost Revenues: Expert Analyst Ian Somaiya Discusses M&A Drivers with The Wall Street TranscriptWall Street Transcript(Tue, Apr 30)
- Ampio Pharmaceuticals Completes Enrollment in Run-In SPRING study of Ampion in Osteoarthritis of the KneePR Newswire(Thu, Apr 25)
- AMPIO PHARMACEUTICALS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Regulation FD Disclosure,EDGAR Online(Thu, Apr 4)
- Lucrative AMD And DME Markets Attract Wall Street To Regeneron And Other Playersat Seeking Alpha(Wed, Apr 3)
- 4 Healthcare Stock Stories for Tuesday Investment Wellnessat Wall St. Cheat Sheet(Tue, Apr 2)
- Stocks Maintain Early Lead; Drugmakers Alexion, Regeneron Climbat Investor's Business Daily(Tue, Apr 2)
- Ampio's Eye Drug Trial Design Won't Pass FDA Musterat TheStreet(Tue, Apr 2)
- Ampio Receives FDA Clearance to Initiate Clinical Trial of Ampion™ for the Treatment of Osteoarthritis of the Knee: Patient Treatments have begun.PR Newswire(Tue, Apr 2)
- Colorado stocks: Ampio up 7%; Molycorp down 5%at bizjournals.com(Thu, Mar 28)
- AMPIO PHARMACEUTICALS, INC. Files SEC form 8-K, Regulation FD DisclosureEDGAR Online(Sun, Mar 17)
Press Releases
- Ampio Pharmaceuticals Announces Participation at the UBS Global Healthcare ConferencePR Newswire(Mon, May 13)
- Ampio Pharmaceuticals Completes Enrollment in Run-In SPRING study of Ampion in Osteoarthritis of the KneePR Newswire(Thu, Apr 25)
- Ampio Receives FDA Clearance to Initiate Clinical Trial of Ampion™ for the Treatment of Osteoarthritis of the Knee: Patient Treatments have begun.PR Newswire(Tue, Apr 2)
Reports
- ValuEngine Industry Report for Medical-drugsValuEngine, Inc.(May 23)
- AMPIO PHARMACEUTICALS INC (AMPE) - REPORT FOR ACTIVE TRADERSPechala's Reports(May 20)
- AMPIO PHARMACEUTICALS INC (AMPE) 12-months forecastPechala's Reports(May 18)